Abiopharma

🔍 Ashish Khandpur K (Director)

Company: AVIENT CORP (AVNT)

Report Date: 2026-02-19

Detailed Transactions and Holdings:

• Acquired 18,403 shares of Common Stock (Direct)
  Date: 2026-02-19 | Code: M | equity_swap_involved: 0 | shares_owned_after: 62,670.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 8,286 shares of Common Stock at $42.51 per share (Direct)
  Date: 2026-02-19 | Code: F | equity_swap_involved: 0 | shares_owned_after: 54,384.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 18,403 shares of Restricted Stock Units (Derivative)
  Date: 2026-02-19 | Code: M | equity_swap_involved: 0 | shares_owned_after: 36,807.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Avient common stock.
• F2: Includes dividend equivalents earned with respect to the vested restricted stock units.
• F3: Represents shares of Avient common stock that were withheld solely to satisfy the tax withholding obligation applicable to the vesting of restricted stock units on February 19, 2026.
• F4: The restricted stock units vest in substantially equal installments on each of February 19, 2026, February 19, 2027 and February 19, 2028, unless earlier vested or terminated pursuant to the terms of the grant agreement.